98%
921
2 minutes
20
TRIM21 is a highly efficient and versatile E3 ubiquitin ligase that plays a crucial role in targeted protein degradation through its specific binding capabilities. To investigate its role in chemically mediated degradation, we utilized two high-affinity binders identified from a DNA-encoded compound library (DEL) to design and synthesize several TrimTACs (TRIM21-based degraders) targeting BRD4. Degradation assays revealed that TrimTACs incorporating distinct TRIM21-binding moieties produced markedly different levels of BRD4 degradation. Further, to elucidate mechanisms underlying ternary complex formation and selective degradation, we employed precise ternary complex modeling combined with Gaussian accelerated molecular dynamics (GaMD) simulations. These computational analyses demonstrated that the diversity of TRIM21-binding moieties significantly affects the stability and conformation of the complex. Structurally stable complexes efficiently induce BRD4 degradation, and the binding orientation of BRD4 directly affects ubiquitin transfer and degradation efficiency. Moreover, key residues critical for complex formation were identified, shedding light on the cooperative interactions driving TRIM21-mediated degradation. Building on these findings, we conducted degradation experiments to validate novel TrimTAC designs derived from our ternary complex-based free energy perturbation (FEP) calculations. The results confirmed the reliability and accuracy of the ternary complex model, providing key insights for the rational design and optimization of TrimTACs, thereby advancing the development of targeted protein degraders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jcim.5c00473 | DOI Listing |
RSC Chem Biol
August 2025
Graduate School of Medical Life Science, Yokohama City University 1-7-29 Yokohama 230-0045 Japan.
We developed a nanoparticle based on a cell-penetrating peptide-PROTAC conjugate with a disulfide linker, , and dextran sulfate, enhancing cellular uptake and BRD4 degradation. This delivery platform significantly improves PROTAC bioavailability and offers a promising strategy to overcome membrane permeability challenges for targeted protein degradation.
View Article and Find Full Text PDFbioRxiv
August 2025
Department of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.
Targeted protein degradation (TPD) is a promising therapeutic strategy that requires the discovery of small molecules that induce proximity between E3 ubiquitin ligases and proteins of interest. FBXO22 is an E3 ligase that is overexpressed in many cancers and implicated in tumorigenesis. While FBXO22 was previously identified as capable of recognizing ligands bearing a primary amine degron, further investigation and development of recruitment ligands is required to enable its broader utility for TPD.
View Article and Find Full Text PDFJACS Au
August 2025
Department of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.
Targeted protein degradation is a powerful therapeutic approach: expanding the druggable proteome, providing enhanced selectivity, and having the ability to overcome conventional resistance mechanisms. A major class of such molecules is proteolysis-targeting chimeras (PROTACs). PROTACs are catalytic heterobifunctional small molecules that simultaneously bind a protein of interest (POI) and an E3 ligase.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA.
Smooth muscle cell (SMC) differentiation plays a crucial role in angiogenesis and vasculogenesis during embryonic development. The underlying mechanisms controlling SMC differentiation, especially progenitor-specific regulation, however, remain largely unclear. In this study, we identified bromodomain-containing protein 4 (BRD4) as a novel regulator for SMC differentiation.
View Article and Find Full Text PDFNeoplasia
October 2025
Institute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University, Hangzhou 311121, China; Skin Disease Research Institute, The 2nd Hospital, Zhejiang University S
The BRAF pathway and epigenetic machinery are central to melanoma pathogenesis. However, how these processes intersect and their potential for synthetic lethality remains unclear. Here, we identified a BRAF-driven epigenetic mechanism in melanoma that involves a H3K27 methylation-to-acetylation switch, facilitating metabolic adaptation to targeted therapies.
View Article and Find Full Text PDF